References
- Alanin, M. C., Klausen, C., Caye-Thomasen, P., Thomsen, C., Fugleholm, K., Poulsgaard, L., . . . Hofland, K. F. (2015). The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. European Archives of Oto-Rhino-Laryngology, 272(12), 3627–3633. doi:10.1007/s00405-014-3398-3
- Chamberlain, M. C., Glantz, M. J., & Fadul, C. E. (2007). Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology, 69(10), 969–973. doi:10.1212/01.wnl.0000271382.62776.b7
- Dombi, E., Ardern-Holmes, S. L., Babovic-Vuksanovic, D., Barker, F. G., Connor, S., Evans, D. G., . . . Collaboration, R. EiNS International. (2013). Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology, 81(21 Suppl 1), S33–40. doi:10.1212/01.wnl.0000435744.57038.af
- Evans, D. G. (2009). Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet Journal of Rare Diseases, 4, 16. doi:10.1186/1750-1172-4-16
- Evans, D. G., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006). Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. Journal of Medical Genetics, 43(4), 289–294. doi:10.1136/jmg.2005.036319
- Evans, D. G., Kalamarides, M., Hunter-Schaedle, K., Blakeley, J., Allen, J., Babovic-Vuskanovic, D., . . . Giovannini, M. (2009). Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res, 15(16), 5032–5039. doi:10.1158/1078-0432.CCR-08-3011
- Evans, D. G., King, A. T., Bowers, N. L., Tobi, S., Wallace, A. J., Perry, M., . . . English Specialist, N. F. Research Group. (2019). Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genetics in Medicine, 21(7), 1525–1533. doi:10.1038/s41436-018-0384-y
- Evans, D. G., Sainio, M., & Baser, M. E. (2000). Neurofibromatosis type 2. Journal of Medical Genetics, 37(12), 897–904. doi:10.1136/jmg.37.12.897
- Farschtschi, S., Kollmann, P., Dalchow, C., Stein, A., & Mautner, V. F. (2015). Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. European Archives of Oto -Rhino-Laryngology, 272(12), 3857–3860. doi:10.1007/s00405-015-3604-y
- Goutagny, S., & Kalamarides, M. (2018). Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neuro-Chirurgie, 64(5), 370–374. doi:10.1016/j.neuchi.2016.09.004
- Halliday, D., Parry, A., & Evans, D. G. (2019). Neurofibromatosis type 2 and related disorders. Current Opinion in Oncology, 31 (6), 562–567. doi:10.1097/CCO.0000000000000579
- Hochart, A., Gaillard, V., Baroncini, M., Andre, N., Vannier, J. P., Vinchon, M., . . . Leblond, P. (2015). Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. Journal of Neuro-Oncology, 124(2), 229–236. doi:10.1007/s11060-015-1828-8
- Huang, V., Bergner, A. L., Halpin, C., Merker, V. L., Sheridan, M. R., Widemann, B. C., . . . Plotkin, S. R. (2018). Improvement in Patient -reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otology & Neurotology, 39(5), 632–638. doi:10.1097/MAO.0000000000001781
- Karajannis, M. A., Legault, G., Hagiwara, M., Ballas, M. S., Brown, K., Nusbaum, A. O., . . . Allen, J. C. (2012). Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology, 14(9), 1163–1170. doi:10.1093/neuonc/nos146
- Kazim, S. F., Shamim, M. S., Enam, S. A., & Bari, M. E. (2011). Microsurgical excisions of vestibular schwannomas: A tumor-size-based analysis of neurological outcomes and surgical complications. Surgical Neurology International, 2, 41. doi:10.4103/2152-7806.78516
- Li, K. L., Djoukhadar, I., Zhu, X., Zhao, S., Lloyd, S., McCabe, M., . . . Jackson, A. (2016). Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro-Oncology, 18(2), 275–282. doi:10.1093/neuonc/nov168
- MacKeith, S., Das, T., Graves, M., Patterson, A., Donnelly, N., Mannion, R., . . . Tysome, J. (2018). A comparison of semi-automated volumetric vs linear measurement of small vestibular schwannomas. European Archives of Oto-Rhino-Laryngology, 275(4), 867–874. doi:10.1007/s00405-018-4865-z
- Mautner, V. F., Nguyen, R., Kutta, H., Fuensterer, C., Bokemeyer, C., Hagel, C., . . . Panse, J. (2010). Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncology, 12(1), 14–18. doi:10.1093/neuonc/nop010
- Morris, K. A., Golding, J. F., Axon, P. R., Afridi, S., Blesing, C., Ferner, R. E., . . . Parry, A. (2016). Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract, 3(4), 281–289. doi:10.1093/nop/npv065
- Morris, K. A., Golding, J. F., Blesing, C., Evans, D. G., Ferner, R. E., Foweraker, K., . . . group, Uk Nf research. (2017). Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology, 131(1), 117–124. doi:10.1007/s11060-016-2276-9
- National Cancer, Institute. (2010). Common terminology criteria for adverse events : (CTCAE).
- Nigro, O., Tartaro, T., Tuzi, A., Giaquinto, A., Suter, M. B., & Pinotti, G. (2019). Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature. Anti-Cancer Drugs, 30(3), 318–321. doi:10.1097/CAD.0000000000000732
- Otsuka, G., Saito, K., Nagatani, T., & Yoshida, J. (2003). Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2. Journal of Neurosurgery, 99 (3), 480–483. doi:10.3171/jns.2003.99.3.0480
- Parry, D. M., Eldridge, R., Kaiser-Kupfer, M. I., Bouzas, E. A., Pikus, A., & Patronas, N. (1994). Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. American Journal of Medical Genetics, 52(4), 450–461. doi:10.1002/ajmg.1320520411
- Phi, J. H., Kim, D. G., Chung, H. T., Lee, J., Paek, S. H., & Jung, H. W. (2009). Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer, 115(2), 390–398. doi:10.1002/cncr.24036
- Plotkin, S. R., Ardern-Holmes, S. L., Barker, F. G., 2nd, Blakeley, J. O., Evans, D. G., Ferner, R. E., . . . Collaboration, R. EiNS International. (2013). Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology, 81(21 Suppl 1), S25–32. doi:10.1212/01.wnl.0000435746.02780.f6
- Plotkin, S. R., Blakeley, J. O., Dombi, E., Fisher, M. J., Hanemann, C. O., Walsh, K. S., . . . Widemann, B. C. (2013). Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology, 81(21 Suppl 1), S1–5. doi:10.1212/01.wnl.0000435743.49414.b6
- Plotkin, S. R., Halpin, C., Blakeley, J. O., Slattery, W. H., 3rd, Welling, D. B., Chang, S. M., . . . Barker, F. G., 2nd. (2009). Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. Journal of Neuro-Oncology, 93(1), 61–77. doi:10.1007/s11060-009-9867-7
- Plotkin, S. R., Merker, V. L., Halpin, C., Jennings, D., McKenna, M. J., Harris, G. J., & Barker, F. G., 2nd. (2012). Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otology & Neurotology, 33(6), 1046–1052. doi:10.1097/MAO.0b013e31825e73f5
- Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., 2nd, Halpin, C., Padera, T. P., Tyrrell, A., . . . di Tomaso, E. (2009). Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. New England Journal of Medicine, 361(4), 358–367. doi:10.1056/NEJMoa0902579
- Slattery, W. H., 3rd, Fisher, L. M., Iqbal, Z., & Oppenhiemer, M. (2004). Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otology & Neurotology, 25(5), 811-817. doi:10.1097/00129492-200409000-00027
- Slusarz, K. M., Merker, V. L., Muzikansky, A., Francis, S. A., & Plotkin, S. R. (2014). Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemotherapy and Pharmacology, 73(6), 1197–1204. doi:10.1007/s00280-014-2456-2
- Van Gompel, J. J., Agazzi, S., Carlson, M. L., Adewumi, D. A., Hadjipanayis, C. G., Uhm, J. H., & Olson, J. J. (2018). Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery, 82 (2), E52–E54. doi:10.1093/neuros/nyx516